Aliases & Classifications for Tic Disorder

MalaCards integrated aliases for Tic Disorder:

Name: Tic Disorder 12 15 71
Behavioral Tic 71
Tics 6

Classifications:



External Ids:

Disease Ontology 12 DOID:2769
ICD9CM 34 307.2 307.20
MeSH 43 D013981
SNOMED-CT 67 35042001 568005
ICD10 32 F95 F95.9
UMLS 71 C0040188 C0278076

Summaries for Tic Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity.

MalaCards based summary : Tic Disorder, also known as behavioral tic, is related to chronic tic disorder and gilles de la tourette syndrome, and has symptoms including ataxia, tremor and myoclonus. An important gene associated with Tic Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Beta-Adrenergic Signaling and Circadian entrainment. The drugs Acetylcholine and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and testes, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 74 Tic disorders are defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) based on... more...

Related Diseases for Tic Disorder

Diseases in the Tic Disorder family:

Chronic Tic Disorder Transient Tic Disorder

Diseases related to Tic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 378)
# Related Disease Score Top Affiliating Genes
1 chronic tic disorder 33.7 SLITRK1 IMMP2L HDC DRD5 DRD4 DRD3
2 gilles de la tourette syndrome 31.5 SLITRK1 SLC6A3 PVALB NRXN1 NLGN4X MIR24-1
3 oppositional defiant disorder 31.0 TPH2 SLC6A3 DRD4 DRD2
4 anxiety 30.9 TPH2 SLC6A3 DRD4 DRD3 DRD2
5 attention deficit-hyperactivity disorder 30.7 TPH2 SLC6A3 NLGN4X IMMP2L DRD5 DRD4
6 trichotillomania 30.6 SLITRK5 SLITRK1 MIR24-1 DRD4 DLGAP3
7 conduct disorder 30.6 SLC6A3 DRD5 DRD4 DRD2
8 movement disease 30.5 SLC6A3 PNKD DRD5 DRD4 DRD3 DRD2
9 obsessive-compulsive disorder 30.5 TPH2 SLITRK5 SLITRK1 SLC6A3 DRD4 DRD3
10 paroxysmal dystonia 30.5 SLC6A3 PVALB PNKD
11 early-onset schizophrenia 30.4 DRD2 DRD1
12 avoidant personality disorder 30.4 SLC6A3 DRD4 DRD3 DRD2
13 tardive dyskinesia 30.3 DRD3 DRD2
14 alcohol use disorder 30.3 SLC6A3 DRD3 DRD2 DRD1
15 mood disorder 30.3 TPH2 SLC6A3 DRD4 DRD3 DRD2 DRD1
16 personality disorder 30.3 TPH2 SLC6A3 DRD4 DRD3 DRD2
17 choreatic disease 30.2 PNKD DRD5 DRD4 DRD3 DRD2 DRD1
18 obsessive-compulsive personality disorder 30.2 SLITRK1 DRD3
19 speech disorder 30.0 PVALB DRD2 CNTNAP2
20 echolalia 30.0 NRXN1 NLGN4X NLGN3 CNTNAP2
21 stuttering 30.0 SLC6A3 PVALB DRD2 CNTNAP2
22 oculogyric crisis 30.0 DRD5 DRD4 DRD3 DRD2 DRD1
23 bruxism 29.9 DRD5 DRD4 DRD3 DRD2 DRD1
24 eating disorder 29.9 SLC6A3 DRD3 DRD2
25 cyclothymic disorder 29.9 DRD4 DRD2
26 fragile x syndrome 29.9 NRXN1 NLGN4X NLGN3 MIR24-1 DLGAP3 CNTNAP2
27 substance abuse 29.8 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
28 panic disorder 29.8 TPH2 SLC6A3 DRD5 DRD4 DRD3 DRD2
29 restless legs syndrome 29.8 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
30 alcohol dependence 29.7 TPH2 SLC6A3 DRD5 DRD4 DRD3 DRD2
31 separation anxiety disorder 29.7 SLC6A3 DRD4
32 dyslexia 29.7 SLC6A3 IMMP2L DRD4 DRD3 DRD2 CNTNAP2
33 dystonia 29.7 SLC6A3 PVALB PNKD DRD5 DRD3 DRD2
34 migraine with or without aura 1 29.6 SLC6A3 PNKD DRD5 DRD4 DRD3 DRD2
35 asperger syndrome 29.6 NRXN1 NLGN4X NLGN3
36 impulse control disorder 29.2 SLITRK5 SLITRK1 SLC6A3 DRD5 DRD4 DRD3
37 autism spectrum disorder 29.1 TPH2 SLC6A3 NRXN1 NLGN4X NLGN3 IMMP2L
38 autism 29.1 TPH2 SLC6A3 NRXN1 NLGN4X NLGN3 IMMP2L
39 disease of mental health 29.1 SLC6A3 PVALB NRXN1 NLGN3 MIR24-1 DRD5
40 psychotic disorder 29.0 TPH2 SLC6A3 PVALB NRXN1 MIR24-1 DRD5
41 bipolar disorder 28.9 TPH2 SLC6A3 PVALB NRXN1 DRD5 DRD4
42 schizophrenia 28.7 TPH2 SLC6A3 PVALB NRXN1 NLGN4X DRD5
43 pervasive developmental disorder 28.3 SLC6A3 PVALB NRXN1 NLGN4X NLGN3 MIR24-1
44 transient tic disorder 12.8
45 trigeminal neuralgia 12.2
46 pediatric acute-onset neuropsychiatric syndrome 11.4
47 chorea, benign hereditary 11.3
48 ceroid lipofuscinosis, neuronal, 4b, autosomal dominant 11.1
49 mcleod syndrome 11.1
50 convulsions, familial infantile, with paroxysmal choreoathetosis 11.1

Graphical network of the top 20 diseases related to Tic Disorder:



Diseases related to Tic Disorder

Symptoms & Phenotypes for Tic Disorder

UMLS symptoms related to Tic Disorder:


ataxia, tremor, myoclonus, dystonia, athetosis, symptoms, synkinesis, recurrent muscle twitches (symptom), tic, motor, tic, gestural, tic, transient, tic, vocal

MGI Mouse Phenotypes related to Tic Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.22 CNTNAP2 DLGAP3 DRD1 DRD2 DRD3 DRD4
2 nervous system MP:0003631 10.06 CNTNAP2 DLGAP3 DRD1 DRD2 DRD3 DRD4
3 integument MP:0010771 9.91 CNTNAP2 DLGAP3 DRD1 DRD2 HDC IMMP2L
4 normal MP:0002873 9.56 DRD1 DRD2 DRD5 NLGN3 NRXN1 PVALB
5 taste/olfaction MP:0005394 9.02 CNTNAP2 DRD2 NLGN3 SLC6A3 TPH2

Drugs & Therapeutics for Tic Disorder

Drugs for Tic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 215)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
2
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
3
Ticagrelor Approved Phase 4 274693-27-5 9871419
4
Donepezil Approved Phase 4 120014-06-4 3152
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
7
Levetiracetam Approved Phase 4 102767-28-2 441341
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
10
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
13
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
14
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
15
Haloperidol Approved Phase 4 52-86-8 3559
16
Fluvoxamine Approved, Investigational Phase 4 54739-18-3 3404 5324346
17
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
18
Desflurane Approved Phase 4 57041-67-5 42113
19
Ondansetron Approved Phase 4 99614-02-5 4595
20
Galantamine Approved Phase 4 357-70-0 9651
21
Choline Approved, Nutraceutical Phase 4 62-49-7 305
22
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
23 Liver Extracts Phase 4
24 Antimetabolites Phase 4
25 Purinergic P2Y Receptor Antagonists Phase 4
26 Hypolipidemic Agents Phase 4
27 Vasodilator Agents Phase 4
28 Lipid Regulating Agents Phase 4
29 Dopamine Agents Phase 4
30 Dopamine Antagonists Phase 4
31 Central Nervous System Depressants Phase 4
32 Serotonin Receptor Agonists Phase 4
33 Antidepressive Agents Phase 4
34 Anti-Infective Agents Phase 4
35 Anti-Bacterial Agents Phase 4
36 Antibiotics, Antitubercular Phase 4
37 Antihypertensive Agents Phase 4
38 Adrenergic alpha-2 Receptor Agonists Phase 4
39 Adrenergic Agonists Phase 4
40 Anticonvulsants Phase 4
41 Adrenergic Agents Phase 4
42 Sympatholytics Phase 4
43 Protective Agents Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Serotonin Uptake Inhibitors Phase 4
46 Anesthetics Phase 4
47 Platelet Aggregation Inhibitors Phase 4
48 Anesthetics, General Phase 4
49 Anesthetics, Inhalation Phase 4
50 Neuroprotective Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 168)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
2 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
3 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
4 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
5 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
6 Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
7 Guanfacine in Children With Tic Disorders: A Multi-site Study Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
8 A 12-Week, Double-Blind Trial of Olanzapine and Placebo in the Treatment of Trichotillomania Completed NCT00182507 Phase 4 Olanzapine
9 Rivastigmine in the Treatment of Postoperative Delirium: a Pilot Clinical Trial Completed NCT00835159 Phase 4 Rivastigmine Patch
10 Impact of Dexmedetomidine Sedation on the Post-Operative Cognition Dysfunction——a Multiple Center,Randomized, Controlled,Double Blinded Clinical Trial. Completed NCT02275182 Phase 4 Dexmedetomidine;Saline
11 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
12 Neurobiology/Treatment of Obsessive-Compulsive Disorder Completed NCT00000373 Phase 4 olanzapine + fluoxetine;placebo + fluoxetine
13 Recovery Following Desflurane vs Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4 Desflurane;Sevoflurane
14 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
15 The Effect of Ramelteon on Delirium and Sleep in Patients Admitted to the ICU Recruiting NCT03931070 Phase 4 Ramelteon;Placebo - Cap
16 Pilot Examination of Galantamine in the Management of Tic Disorders Terminated NCT00226824 Phase 4 galantamine
17 A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Unknown status NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
18 A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
19 A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
20 Behavior Therapy for Children With Chronic Tic Disorders Completed NCT00218777 Phase 2, Phase 3
21 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder Completed NCT00004376 Phase 3 guanfacine
22 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
23 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
24 Long-term Safety and Effectiveness of OROS (Methylphenidate HCl) in Children With ADHD Completed NCT00269815 Phase 3 methylphenidate HCl
25 Multicenter Study Comparing the Efficacy and Safety of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD Completed NCT00269802 Phase 3 OROS methylphenidate HCl;Ritalin;Placebo
26 An Open-label Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Tourette Syndrome (CAPSS-286) Completed NCT00206336 Phase 3 Topiramate (drug)
27 Comparative Crossover Study of OROS (Methylphenidate HCl), Ritalin, and Placebo in Children With ADHD Completed NCT00269789 Phase 3 Ritalin;OROS Methylphenidate HCl;Placebo
28 Screening, Efficacy, and Safety Study Evaluating OROS (Methylphenidate HCl), Ritalin and Placebo in Children With ADHD Completed NCT00269776 Phase 3 Placebo;OROS (methylphenidate HCl);Ritalin (methylphenidate)
29 Treatment of Gilles de la Tourette Syndrome by Bilateral Stimulation of the Internal Part of the Globus PALLIDUS Completed NCT00478842 Phase 3
30 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine the Safety and Efficacy of Topiramate in the Treatment of Tourette Syndrome (CAPSS-176) Completed NCT00206323 Phase 3 Topiramate (drug);placebo/sugar pill
31 A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Recruiting NCT03087201 Phase 3 nabiximols;placebo
32 An Open-Label, Long-Term Safety Study Including a Double-Blind, Placebo-Controlled, Randomized Withdrawal Period of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Recruiting NCT03567291 Phase 3 TEV-50717;Placebo
33 The Impact of Vitamin K2 and Inactive Vitamin D Supplementation on Vascular Calcification in Pediatric Patients on Regular Hemodialysis Recruiting NCT04145492 Phase 2, Phase 3 Vitamin K2;Cholecalciferol (inactive vitamin D);Vitamin K2 and Cholecalciferol
34 A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome Active, not recruiting NCT03571256 Phase 3 deutetrabenazine Low;deutetrabenazine High;Placebo
35 A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents Active, not recruiting NCT03452943 Phase 2, Phase 3 TEV-50717;Placebo
36 Metformin in Alzheimer's Dementia Prevention Not yet recruiting NCT04098666 Phase 2, Phase 3 Placebo oral tablet;extended release metformin
37 Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Unknown status NCT02102698 Phase 2 Ecopipam
38 Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study Unknown status NCT02112253 Phase 1, Phase 2
39 Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS Unknown status NCT01769027 Phase 2 Sertraline+Antibiotic (penicillin/azithromycin);Sertraline+placebo
40 TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest Unknown status NCT02836340 Phase 1, Phase 2 2-Iminobiotin
41 rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder: a Multicenter, Double-blind, Controlled Trial. Unknown status NCT03211221 Phase 2
42 Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
43 Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
44 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
45 Double-Blind, Placebo-Controlled Trial of N-acetylcysteine (NAC) for the Treatment of Children With Tourette Syndrome Completed NCT01172288 Phase 2 N-Acetylcysteine (NAC);Placebo
46 Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome Completed NCT02619084 Phase 2
47 Open Label Safety and Tolerability Trial of CPP-109 (Vigabatrin) in Adults With Treatment Refractory Tourette's Disorder Completed NCT01585207 Phase 1, Phase 2 vigabatrin
48 A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder Completed NCT01904773 Phase 2 AZD5213 and placebo
49 Examining the Efficacy of a Therapeutic Combination of Dronabinol (Synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Tourette Syndrome Completed NCT03066193 Phase 2 Dronabinol and Palmitoylethanolamide
50 Phase II Pilot Controlled Study of Short Vs Longer Term Pimozide (Orap) Therapy in Tourette Syndrome Completed NCT00004652 Phase 2 pimozide

Search NIH Clinical Center for Tic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Clonazepam

Genetic Tests for Tic Disorder

Anatomical Context for Tic Disorder

MalaCards organs/tissues related to Tic Disorder:

40
Brain, Breast, Testes, Liver, Lung, Prostate, Globus Pallidus

Publications for Tic Disorder

Articles related to Tic Disorder:

(show top 50) (show all 4401)
# Title Authors PMID Year
1
Is botulinum toxin effective and safe for motor and phonic tics in patients affected by Tourette syndrome? A Cochrane Review summary with commentary. 61
31957864 2020
2
A Review on Functional Analyses of Tics. 61
30373380 2020
3
A multicenter randomized clinical trial to evaluate the efficacy of telemonitoring in patients with advanced heart and lung chronic failure. Study protocol for the ATLAN_TIC project. 61
31938754 2020
4
Safety and efficacy of taurine as an add-on treatment for tics in youngsters. 61
31618495 2020
5
Cancer stem cells: A review from origin to therapeutic implications. 61
31286518 2020
6
Contrast-Enhanced Ultrasound (CEUS) Identifies Perfusion Differences Between Tibial Fracture Unions and Non-Unions. 61
30081395 2020
7
Clinical Features of Tourette Syndrome. 61
31608744 2020
8
Mutations in ASH1L confer susceptibility to Tourette syndrome. 61
31673123 2020
9
Deep Brain Stimulation for Tourette Syndrome: Potential Role in the Pediatric Population. 61
31526168 2020
10
Models of hyperkinetic disorders in primates. 61
31857131 2020
11
Psychiatric comorbidity in children with psychogenic and functional breathing disorders. 61
31710164 2020
12
Exploring circannual rhythms and chronotype effect in patients with Obsessive-Compulsive Tic Disorder (OCTD): A pilot study. 61
31733921 2020
13
Transcription factor early growth response-1 plays an oncogenic role in salivary gland pleomorphic adenoma. 61
31786685 2020
14
Methylphenidate in children with monogenic obesity due to LEPR or MC4R deficiency improves feeling of satiety and reduces BMI-SDS-A case series. 61
31670905 2020
15
Suppression of LIM Kinase 1 and LIM Kinase 2 Limits Glioblastoma Invasion. 61
31641031 2020
16
Clinical application of dynamic contrast enhanced ultrasound in monitoring the treatment response of chemoradiotherapy of pancreatic ductal adenocarcinoma. 61
31985457 2020
17
Hydrodynamic shear-based purification of cancer cells with enhanced tumorigenic potential. 61
31965190 2020
18
Androgens Modulate Rat Granulosa Cell Steroidogenesis. 61
31916094 2020
19
OptFill: A Tool for Infeasible Cycle-Free Gapfilling of Stoichiometric Metabolic Models. 61
31954977 2020
20
Assessment and management of tic disorders and Tourette syndrome by Australian paediatricians. 61
31206903 2020
21
Isoallopregnanolone reduces tic-like behaviours in the D1CT-7 mouse model of Tourette syndrome. 61
31175669 2020
22
[Tourette syndrome: Research challenges to improve clinical practice]. 61
32014239 2020
23
Treatment of tics associated with Tourette syndrome. 61
31955299 2020
24
Treatment options for tic disorders. 61
31795779 2020
25
Comprehensive Behavioral Intervention for Tics reduces perception-action binding during inhibitory control in Gilles de la Tourette syndrome. 61
31980733 2020
26
Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. 61
31992334 2020
27
Arachnoid bands and venous compression as rare causes of hemifacial spasm: analysis of etiology in 353 patients. 61
31754846 2020
28
[Clinical characteristics of children with Tourette's Syndrome]. 61
31854321 2020
29
Deep brain stimulation for Tourette's syndrome. 61
31956406 2020
30
Deep brain stimulation of the thalamic centromedian-parafascicular nucleus improves behavioural and neuronal traits in a rat model of Tourette. 61
31614188 2020
31
Trichotillomania is more related to Tourette disorder than to obsessive-compulsive disorder. 61
31576938 2020
32
Role of CD44 in tumor-initiating cells of salivary gland pleomorphic adenoma: More than a surface biomarker. 61
31926047 2020
33
The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer. 61
31658996 2020
34
The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma. 61
31901872 2020
35
Association between allergic conjunctivitis and provisional tic disorder in children. 61
31564049 2020
36
Botulinum Toxin for the Treatment of Motor and Phonic Tics: A Case Report. 61
31906695 2020
37
Efficacy of Habit Reversal Training in Children With Chronic Tic Disorders: A Within-Subject Analysis. 61
30146896 2020
38
Protocol for the Process Evaluation of the Online Remote Behavioural Intervention for Tics (ORBIT) randomized controlled trial for children and young people. 61
31898510 2020
39
BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis. 61
31630873 2019
40
Sensory dysregulation in tic disorders is associated with executive dysfunction and comorbidities. 61
31505086 2019
41
Multiple low-level exposures: Hg interactions with co-occurring neurotoxic substances in early life. 61
30385391 2019
42
Diet quality and cognitive function in mid-aged and older men and women. 61
31864295 2019
43
Validation of neuropsychological tests for the China Health and Retirement Longitudinal Study Harmonized Cognitive Assessment Protocol. 61
31309907 2019
44
Voluntary tic suppression and the normalization of motor cortical beta power in Gilles de la Tourette syndrome: an EEG study. 61
31421054 2019
45
Neural correlates of performance monitoring in adult patients with Gilles de la Tourette syndrome: A study of event-related potentials. 61
31972503 2019
46
Deep Brain Stimulation in Movement Disorders: From Experimental Surgery to Evidence-Based Therapy. 61
31580535 2019
47
Predictors of the Clinical Course of Tourette Syndrome: A Longitudinal Study. 61
31411102 2019
48
Relaxation therapy as a treatment for tics in patients with Tourette syndrome: a systematic literature review. 61
31872351 2019
49
Executive function in children with Tourette syndrome and attention-deficit/hyperactivity disorder: Cross-disorder or unique impairments? 61
31901563 2019
50
Sleep difficulties in children with Tourette syndrome and chronic tic disorders: A systematic review of characteristics and associated factors. 61
31859345 2019

Variations for Tic Disorder

ClinVar genetic disease variations for Tic Disorder:

6 ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XY;t(3;18)(q13.31;q22.1)dnTranslocation Pathogenic 268039
2 46;X;t(Y;16)(q11.23;p11.2);t(6;21)(p21.3;p13)dnTranslocation Likely pathogenic 267834

Expression for Tic Disorder

Search GEO for disease gene expression data for Tic Disorder.

Pathways for Tic Disorder

Pathways related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.57 DRD5 DRD4 DRD3 DRD2 DRD1
2
Show member pathways
12.51 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
3 12.08 DRD5 DRD4 DRD3 DRD2 DRD1
4
Show member pathways
11.98 DRD5 DRD4 DRD2 DRD1
6 11.9 NRXN1 NLGN4X NLGN3 CNTNAP2
7
Show member pathways
11.82 NRXN1 NLGN4X NLGN3 DLGAP3
8
Show member pathways
11.76 SLC6A3 DRD2 DRD1
9
Show member pathways
11.68 DRD4 DRD3 DRD2
10
Show member pathways
11.6 DRD5 DRD4 DRD3 DRD2 DRD1
11 10.6 DRD5 DRD3 DRD2 DRD1
12
Show member pathways
10.53 TPH2 SLC6A3 DRD5 DRD4 DRD3 DRD2

GO Terms for Tic Disorder

Cellular components related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.44 SLITRK5 SLITRK1 SLC6A3 PNKD NRXN1 NLGN4X
2 integral component of membrane GO:0016021 10.37 SLITRK5 SLITRK1 SLC6A3 NRXN1 NLGN4X NLGN3
3 plasma membrane GO:0005886 10.35 SLITRK5 SLITRK1 SLC6A3 NRXN1 NLGN4X NLGN3
4 integral component of plasma membrane GO:0005887 10.06 SLC6A3 NRXN1 NLGN4X NLGN3 DRD5 DRD4
5 cell junction GO:0030054 10.02 SLITRK1 NRXN1 NLGN4X NLGN3 DLGAP3 CNTNAP2
6 cell surface GO:0009986 9.98 SLC6A3 NRXN1 NLGN4X NLGN3 CNTNAP2
7 synapse GO:0045202 9.98 SLITRK5 SLITRK1 NRXN1 NLGN4X NLGN3 DRD5
8 dendrite GO:0030425 9.93 NLGN4X DRD4 DRD2 DRD1 CNTNAP2
9 ciliary membrane GO:0060170 9.69 DRD5 DRD2 DRD1
10 non-motile cilium GO:0097730 9.63 DRD5 DRD2 DRD1
11 integral component of presynaptic membrane GO:0099056 9.62 SLC6A3 NRXN1 DRD2 DRD1
12 endocytic vesicle GO:0030139 9.56 NRXN1 NLGN3 DRD3 DRD2
13 dopaminergic synapse GO:0098691 9.54 SLC6A3 DRD3 DRD2
14 spanning component of membrane GO:0089717 9.52 NLGN4X NLGN3
15 glutamatergic synapse GO:0098978 9.5 SLITRK1 NRXN1 DRD4 DRD3 DRD2 DRD1
16 asymmetric, glutamatergic, excitatory synapse GO:0098985 9.49 NLGN4X NLGN3
17 symmetric, GABA-ergic, inhibitory synapse GO:0098983 9.48 NLGN4X NLGN3
18 integral component of postsynaptic membrane GO:0099055 9.46 SLC6A3 NLGN3 DRD2 DRD1
19 GABA-ergic synapse GO:0098982 9.02 SLITRK1 NRXN1 DRD3 DRD2 DRD1

Biological processes related to Tic Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 10.03 SLC6A3 DRD3 DRD2 DRD1
2 chemical synaptic transmission GO:0007268 10.02 SLITRK5 NRXN1 DRD5 DRD4
3 locomotory behavior GO:0007626 9.96 SLC6A3 DRD3 DRD2 DRD1
4 synapse assembly GO:0007416 9.93 SLITRK1 NRXN1 NLGN3 DRD2 DRD1
5 positive regulation of synapse assembly GO:0051965 9.92 SLITRK5 SLITRK1 NRXN1 NLGN3
6 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.92 DRD5 DRD3 DRD2 DRD1
7 response to ethanol GO:0045471 9.91 SLC6A3 DRD3 DRD2
8 cellular calcium ion homeostasis GO:0006874 9.91 DRD5 DRD4 DRD3
9 axonogenesis GO:0007409 9.9 SLITRK5 SLITRK1 DRD2
10 modulation of chemical synaptic transmission GO:0050804 9.89 NLGN4X NLGN3 DRD2
11 visual learning GO:0008542 9.88 NLGN3 DRD3 DRD2 DRD1
12 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.87 DRD5 DRD3 DRD2 DRD1
13 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.86 DRD3 DRD2 DRD1
14 associative learning GO:0008306 9.85 DRD5 DRD2 DRD1
15 negative regulation of blood pressure GO:0045776 9.85 DRD5 DRD3 DRD2
16 dopamine receptor signaling pathway GO:0007212 9.85 DRD4 DRD3 DRD2 DRD1
17 arachidonic acid secretion GO:0050482 9.84 DRD4 DRD3 DRD2
18 positive regulation of synaptic transmission, glutamatergic GO:0051968 9.83 NRXN1 NLGN3 DRD1
19 negative regulation of protein secretion GO:0050709 9.83 DRD4 DRD3 DRD2
20 behavioral response to cocaine GO:0048148 9.83 DRD4 DRD3 DRD2 DRD1
21 response to cocaine GO:0042220 9.83 SLC6A3 DRD5 DRD3 DRD2 DRD1
22 transmission of nerve impulse GO:0019226 9.82 DRD5 DRD1 CNTNAP2
23 neuron cell-cell adhesion GO:0007158 9.82 NRXN1 NLGN4X NLGN3
24 negative regulation of voltage-gated calcium channel activity GO:1901386 9.81 DRD4 DRD3 DRD2
25 behavioral response to ethanol GO:0048149 9.81 DRD4 DRD3 DRD2
26 dopamine metabolic process GO:0042417 9.81 DRD4 DRD3 DRD2 DRD1
27 grooming behavior GO:0007625 9.8 SLITRK5 DRD2 DRD1
28 vocalization behavior GO:0071625 9.8 NRXN1 NLGN4X NLGN3 CNTNAP2
29 learning GO:0007612 9.8 NRXN1 NLGN4X NLGN3 DRD3 DRD1 CNTNAP2
30 presynaptic membrane assembly GO:0097105 9.79 NRXN1 NLGN4X NLGN3
31 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.78 DRD5 DRD3 DRD1
32 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.78 DRD5 DRD3 DRD2 DRD1
33 postsynaptic membrane assembly GO:0097104 9.77 NRXN1 NLGN4X NLGN3
34 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.77 DRD4 DRD3 DRD2
35 response to amphetamine GO:0001975 9.77 DRD5 DRD4 DRD3 DRD2 DRD1
36 striatum development GO:0021756 9.76 SLITRK5 DRD2 DRD1 CNTNAP2
37 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.75 DRD3 DRD2 DRD1
38 temperature homeostasis GO:0001659 9.74 DRD2 DRD1
39 response to iron ion GO:0010039 9.74 SLC6A3 DRD2
40 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
41 long-term synaptic depression GO:0060292 9.73 DRD5 DRD1
42 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.73 DRD3 DRD2
43 presynapse assembly GO:0099054 9.73 NLGN4X NLGN3
44 response to histamine GO:0034776 9.73 DRD4 DRD3 DRD2
45 positive regulation of renal sodium excretion GO:0035815 9.72 DRD3 DRD2
46 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
47 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.72 DRD4 DRD3
48 regulation of potassium ion transport GO:0043266 9.71 DRD3 DRD2
49 negative regulation of excitatory postsynaptic potential GO:0090394 9.71 NLGN4X NLGN3
50 inhibitory postsynaptic potential GO:0060080 9.71 NLGN3 DRD4

Molecular functions related to Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.62 SLC6A3 DRD4 DRD3 DRD2
2 cell adhesion molecule binding GO:0050839 9.58 NRXN1 NLGN4X NLGN3
3 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
4 neurexin family protein binding GO:0042043 9.43 NLGN4X NLGN3
5 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.43 DRD4 DRD3 DRD2
6 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.37 DRD5 DRD1
7 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
8 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Tic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....